Future studies that address potential drug therapies that have the potential to reduce AF and HF risk in patients with elevated PAC and PVC counts would be of interest, for example sodium-glucose cotransporter-2 inhibitors as a preferred treatment for diabetic patients with PVCs.23 Here, SLC5A2 is linked to atrial fibrillation.